PRESPECIFIED KPS SUBGROUPS SHOWED
CONSISTENT SURVIVAL BENEFIT WITH THE ITT POPULATION1,7
PRESPECIFIED KPS SUBGROUPS SHOWED CONSISTENT SURVIVAL BENEFIT WITH THE ITT POPULATION1,7

Median OS was 8.5 vs 6.7 months, respectively; HR 0.72 (95% CI: 0.62-0.83); P<0.0001
Median OS was 8.5 vs 6.7 months, respectively; HR 0.72 (95% CI: 0.62-0.83); P<0.0001
Median OS for KPS 70-80. ABRAXANE + gemcitabine vs gemcitabine
Median OS (95% CI) by KPS subgroups
Median OS for KPS 70-80. ABRAXANE + gemcitabine vs gemcitabine
HR (95% CI) 0.75 (0.62-0.92)
Median OS (95% CI) by KPS subgroups
HR (95% CI) 0.61 (0.48-0.78)
Analysis Limitations: An exploratory analysis should not be interpreted to determine a treatment difference between arms in these selected subgroups because of insufficient sample size and a higher probability of making a false positive finding.
  • Forest Plot of All Prespecified Subgroups

    PRESPECIFIED SUBGROUPS EXPERIENCED
    CONSISTENT SURVIVAL BENEFIT WITH THE ITT POPULATION1
    PRESPECIFIED SUBGROUPS EXPERIENCED CONSISTENT SURVIVAL BENEFIT WITH THE ITT POPULATION1

    Exploratory analysis included subgroups such as age and performance status1
    Forest Plot of all  Prespecified Subgroups for ABRAXANE + gemcitabine vs gemcitabine Forest Plot of all  Prespecified Subgroups for ABRAXANE + gemcitabine vs gemcitabine
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL